Aptevo Therapeutics Net Income 2014-2021 | APVO

Aptevo Therapeutics net income from 2014 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Aptevo Therapeutics Annual Net Income
(Millions of US $)
2020 $-18
2019 $-40
2018 $-54
2017 $7
2016 $-112
2015 $-59
2014 $-51
2013 $
Aptevo Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-7
2021-06-30 $-8
2021-03-31 $-7
2020-12-31 $-7
2020-09-30 $-7
2020-06-30 $-7
2020-03-31 $3
2019-12-31 $-8
2019-09-30 $-7
2019-06-30 $-13
2019-03-31 $-12
2018-12-31 $-14
2018-09-30 $-13
2018-06-30 $-13
2018-03-31 $-14
2017-12-31 $-10
2017-09-30 $38
2017-06-30 $-11
2017-03-31 $-10
2016-12-31 $-15
2016-09-30 $-72
2016-06-30 $-13
2016-03-31 $-13
2015-12-31
2015-09-30 $-13
2015-06-30 $-18
2014-12-31
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.035B $0.004B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69